Although the etiology of Behçet's disease (BD) is still unknown, neutrophils are implicated in its pathogenesis. Growth-related oncogene-α (GRO-α) is a potent chemoattractant and activator for neutrophils.Objective
To determine the role of GRO-α in the pathogenesis of BD, we investigated serum GRO-α levels in patients with BD.Materials and methods
Sera from patients with BD (n = 57) and control subjects (n = 26) were measured by enzyme-linked immunosorbent assay. Serum levels of GRO-α were compared with clinical symptoms.Results
Patients with BD had significantly elevated serum GRO-α levels compared with healthy controls (121.7 ± 79.2 pg/ml vs. 75.9 ± 20.6 pg/ml, P < 0.01). Concerning the subgroups of BD, serum GRO-α levels in active patients with BD (n = 35) were significantly higher than in inactive patients with BD (n = 22; 139.0 ± 92.8 pg/ml vs. 94.3 ± 36.2 pg/ml, P < 0.05). Also, as seen in previous studies, serum interleukin-8 levels in patients with BD (52.4 ± 81.8 pg/ml) were significantly higher than in controls (13.9 ± 19.7 pg/ml, P < 0.01). Enhanced GRO-α levels correlated with clinical symptoms such as erythema nodosum.Conclusion
Our results indicate that serum levels of GRO-α are elevated in patients with active stage BD, suggesting that GRO-α may serve as a reliable marker for disease activity of BD.